Oligomerix raised $2 million in a Series A round of financing to progress its tau protease inhibitor program for treating Alzheimer disease. The financing round comprises both the issue of new convertible preferred shares and debt conversion. Oligomerix is focused on the development of small molecule drugs and immunotherapeutics that target neurotoxic tau oligomers for [...]
↧